MGH Center for Women's Mental Health

Cognitive-Behavioral Therapy for the Treatment of Menopausal Hot Flashes: A Pilot Study

Hot flashes are a common and distressing symptom of menopause, affecting approximately 60-70 % of women undergoing the menopausal transition. Several pharmacologic treatments for hot flashes, including hormone replacement therapy (HRT) and some antidepressants, have been shown to reduce the frequency and intensity of hot flashes. However, some women prefer not to use HRT or antidepressants and seek alternative treatments, such as homeopathic or herbal remedies. Many of these alternative treatments have not yet been evaluated for safety or efficacy.

By MGH Center for Women's Mental Health|2015-08-11T15:16:17-04:00September 29th, 2008|Menopausal Symptoms, Psychotherapy, Treatment, Vasomotor Symptoms|Comments Off

Estrogen for the Treatment of Women with Schizophrenia

There is cumulative evidence suggesting that estrogen might play a role in the development of schizophrenia and therefore may be useful in the treatment of this illness. On average, the first signs of schizophrenia appear 3 to 4 years later in women than in men, with a second peak in women around menopause. Interestingly, men suffering from schizophrenia exacerbation demonstrate low serum estrogen and androgen levels. Estrogen has been demonstrated to have beneficial effects in treating hormonally mediated affective disorders such as postnatal depression or perimenopausal depression. A recent study published in the Archives of General Psychiatry suggests that estrogen may also be beneficial for the treatment of patients with schizophrenia.

By MGH Center for Women's Mental Health|2015-08-11T14:46:54-04:00September 22nd, 2008|Hormone Therapy, Menopausal Symptoms, Schizophrenia and Psychotic Disorders, Treatment|Comments Off

PPHN and SSRIs: Another Study Evaluating the Risk

In 2006, Chambers and colleagues published an article linking SSRI use during late pregnancy to an increased risk of persistent pulmonary hypertension in the newborn (PPHN). Based on the results of this analysis, the authors estimated the risk of PPHN to be about 1% in infants exposed to SSRIs late in pregnancy (after 20 weeks). However, subsequent studies did not demonstrate a significant association between PPHN and SSRI usage. A new study, this one relying upon data from the Swedish Medical Birth Register, has observed an elevated risk of PPHN among SSRI-exposed infants.

By MGH Center for Women's Mental Health|2015-08-11T14:44:41-04:00September 16th, 2008|Antidepressants, Neonatal Symptoms, Outcomes, Pregnancy & Medications|Comments Off

Citalopram (Celexa) Effective for Treating Hot Flashes

For decades, estrogen has been used to treat menopausal symptoms, including night sweats and hot flushes. However, after studies reported that estrogen may have an adverse effect on risk for cardiovascular disease and breast cancer, many patients and clinicians have looked into alternative treatments for hot flashes, including selective serotonin reuptake inhibitors (SSRIs).

By MGH Center for Women's Mental Health|2015-07-28T10:34:32-04:00September 8th, 2008|Medication, Menopausal Symptoms, Treatment, Vasomotor Symptoms|Comments Off

Impact of Infertility Treatment on Risk for Depression and Anxiety

Infertility and its treatment have been shown to be a trigger for both depression and anxiety. Women with pre-existing histories of depression and anxiety who have been stable on medication may find themselves with worsening symptoms brought on by the stress involved in the process of infertility treatment. Many women find the process an emotional roller coaster of hopefulness and disappointment.

By MGH Center for Women's Mental Health|2015-08-11T14:43:11-04:00August 28th, 2008|Anxiety Disorders, Depressive Disorders, Infertility and Mental Health, Outcomes, Psychiatric Disorders During Pregnancy|Comments Off

Pre-Existing Psychiatric Illness is a Risk Factor for Postpartum Suicide Attempt

A recent population-based case-control study published in the American Journal of Obstetrics & Gynecology used Washington State birth certificates linked to hospital discharge data to evaluate the association between hospitalization for a psychiatric illness before delivery and risk of postpartum suicide attempt. The study compared women hospitalized for a postpartum suicide attempt (n = 355) with a group of controls who had not been hospitalized (n = 1420).

By MGH Center for Women's Mental Health|2015-08-11T14:41:39-04:00August 21st, 2008|Depressive Disorders, Prevalence & Risk Factors, Psychiatric Disorders During Pregnancy, Suicide|Comments Off

Antidepressants and Risk for Osteoporosis

Selective serotonin reuptake inhibitors (SSRIs) account for approximately 62% of all antidepressants prescribed in the United States. There have been several recent studies suggesting that SSRIs may lower bone mineral density in individuals over the age of 65. However, depression itself has been shown to decrease bone mineral density and has also been associated with an increased risk of hip fractures in older women.

By MGH Center for Women's Mental Health|2018-06-17T23:22:37-04:00August 15th, 2008|Antidepressants, Anxiety Disorders, Depressive Disorders, Menopausal Symptoms, Outcomes|Comments Off

New England Journal of Medicine Case Report: Postpartum Psychosis in a Woman with Bipolar Disorder

The most recent issue of the New England Journal of Medicine includes the presentation of a case from the Center for Women's Mental Health of a woman with bipolar disorder who developed postpartum psychosis after the birth of her child. The case highlights some of the clinical challenges in treating patients with bipolar disorder during pregnancy and the postpartum period and reviews the current literature on postpartum psychosis.

By MGH Center for Women's Mental Health|2016-03-28T13:23:59-04:00August 11th, 2008|Bipolar Disorder, Diagnosis & Screening, Postpartum Psychiatric Disorders, Postpartum Psychosis, Prevalence & Risk Factors|Comments Off

St. John’s Wort: Is it Safe for Pregnancy?

St. John's wort (Hypericum perforatum) is an herbal preparation which has been shown, in some studies, to be effective for the treatment of mild to moderate depressive symptoms. St. John's wort is now one of the most commonly used herbal products in the United States and is widely used in Europe.

By MGH Center for Women's Mental Health|2015-08-11T14:14:20-04:00August 5th, 2008|Antidepressants, Depressive Disorders, Pregnancy & Medications, Risk of Malformations|Comments Off

Does Depo-Provera Cause Mood Changes?

Depo-Provera (DMPA), also known as the birth control shot, is a highly effective form of contraception that lasts for 3 months, and thus requires only 4 injections per year. DMPA contains a long-lasting form of depot medroxyprogesterone acetate that works as a contraceptive agent by preventing the ovaries from releasing an egg each month. Potential side effects of DMPA include bone density loss, weight gain, and mood worsening. Although depression is listed in the packet insert as a side effect of the injection, available research addressing this side effect are limited and contradictory.

By MGH Center for Women's Mental Health|2019-03-01T13:36:17-04:00July 29th, 2008|Contraception, Depressive Disorders, General, Hormone Therapy, Prevalence & Risk Factors|Comments Off

About MGH Center for Women's Mental Health